| Popis: |
Publicação sob a forma de Poster The aim of this study was the characterization of patients with Hepatitis C (HCV) under treatment. Patients included in this study were followed in a Portuguese District Hospital between January 2012 and September 2014, have received treatment for HCV and who had at least one infectiology consultation in this period. Data were collected from the hospital computer system, and patient´s data were collected anonymously, without patient identification. Data analysis was performed using SPSS v22.0. Were included in this study 87 patients who met the inclusion criteria, 75% (n=65) were males and 25% (n=22) female, with a mean age of 45±10 years. Most patients included in this study were Portuguese, resident in the Hospital district and nearby districts. Patients were diagnosed with HCV with a mean age of 3311 years, were followed on average for 53.5 years in this Hospital, and were diagnosed with HCV on average 126.9 years ago. Among these patients, 44% (n=38) had genotype 1, 2% (n=2) genotype 2, 17% (n=15) genotype 3, 13% (n=11) genotype 4 and 24% (n=21) with unknown genotype. Most frequent treatment regimens used by patients included in the study were the association of pegylated interferon alfa 2b (100mcg/week) and ribavirin (1000 mg/day) (52%; n=45); pegylated interferon alpha 2a (180mcg/week) and ribavirin (1000 mg/day) (42%; n=36). Other associations were used but less frequently: pegylated interferon alfa 2a + ribavirin + boceprevir (2%; n=2); pegylated interferon alfa 2b + ribavirin + boceprevir (3%; n=3); and pegylated interferon alfa 2a + ribavirin + telaprevir (1%; n=1). Among included patients, 55 (63%) have performed, to date, one treatment for HCV, 19 (22%) have performed two treatments for HCV (using two different regimens or by using the same regimen twice), 9 (10%) already underwent treatment three times, 3 (3%) already underwent treatment four times and only one patient (1%) has conducted five treatments for HCV. Excluding patients who were receiving treatment at the time of data collection (September 2014), the average length of all other treatments performed by the patients was 82 months, and most (40%; n=51) of treatments performed by patients had a duration from 6 to 9 months. From the results, the standard treatment for patients with HCV appears to be in accordance with the existing guidelines for the treatment of this pathology. In the future it would be advisable further analysis and extended to other hospitals to assess the degree of compliance with currently existing national guidelines for the treatment of this pathology. info:eu-repo/semantics/publishedVersion |
